Morphologic and immunopathologic findings in myasthenia gravis and in congenital myasthenic syndromes.
Overwhelming evidence now supports Simpson's concept, originally proposed in 1960, that acquired myasthenia gravis (MG) is an autoimmune disease in which antibodies are directed against the nicotine postsynaptic acetylcholine receptor (AChR).1 An autoimmune pathogenesis of acquired MG implies that those myasthenic syndromes which occur in a congenital and familial setting may have a different, non-autoimmune basis. This paper focuses on ultrastructural, immunoelectron microscopic and cytochemical aspects of acquired autoimmune MG and some recently recognised congenital myasthenic syndromes.
D000109:Acetylcholine / Q000276:immunology; D000110:Acetylcholinesterase / Q000172:deficiency; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology*; D003165:Complement System Proteins / Q000032:analysis; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007473:Ion Channels / Q000201:enzymology; D009045:Motor Endplate / Q000201:enzymology / Q000473:pathology; D009157:Myasthenia Gravis / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D011950:Receptors, Cholinergic / Q000276:immunology; D009435:Synaptic Transmission
D007074:Immunoglobulin G; D007473:Ion Channels; D011950:Receptors, Cholinergic; D003165:Complement System Proteins; D000110:Acetylcholinesterase; D000109:Acetylcholine